238 filings
Page 5 of 12
8-K
ansc73wr7q2 6p0nkfr
1 Jun 23
Entry into a Material Definitive Agreement
5:00pm
8-K
gspijaede h12yn1e
26 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
16ewnpg0rz
2 May 23
Other Events
12:00am
D
sw3d47
28 Apr 23
$350.00 k in equity / securities to be acquired, sold $350.00 k, 1 investor
6:10am
D
35i2turh2 py09
28 Apr 23
Indefinite amount in debt / Secured Promissory Notes, sold $3.37 mm, 1 investor
6:08am
8-K
4bzu2m
25 Apr 23
Entry into a Material Definitive Agreement
5:00pm
424B4
dtn0txlkspgxx 2i
20 Apr 23
Prospectus supplement with pricing info
5:00pm
8-K
upsmwf bb2
19 Apr 23
Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering
4:30pm
EFFECT
7306a wdqt
19 Apr 23
Notice of effectiveness
12:15am
CORRESP
8pyq5jz44bqefsvx3
17 Apr 23
Correspondence with SEC
12:00am
8-K
9ylrapyn nfl4zvsj
12 Apr 23
Entry into a Material Definitive Agreement
5:00pm
8-K
uajz0n9
11 Apr 23
Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting
9:19am
8-K
x2qidknz3wp7b9s
28 Mar 23
Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies
5:15pm